Extending the capital cost allowance brought the effective corporate rate down for large companies. So it has benefited the large companies, the capital-intensive companies that are the backbone of the economy. That's been positive.
But that in and of itself doesn't provide a large benefit to small companies in the biotech area, the general commercial area, or the resource area. They are more reliant on either lower corporate rates, which they have benefited from to some extent, or from what we believe would be some additional incentive in the capital-raising program for those companies that need capital.